Research programme: cannabinoid therapeutics - Oxford Cannabinoid Technologies
Latest Information Update: 26 Apr 2021
At a glance
- Originator Oxford Cannabinoid Technologies
- Class Analgesics; Cannabinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Neuralgia; Trigeminal neuralgia
Most Recent Events
- 31 Mar 2021 Research programme: cannabinoid therapeutics - Oxford Cannabinoid Technologies is available for licensing as of 31 Mar 2021. https://www.oxcantech.com/research-and-development
- 04 Mar 2021 Early research in Neuralgia in USA (unspecified route) before March 2021 (Oxford Cannabinoid Technologies, March 2021)
- 04 Mar 2021 Early research in Trigeminal neuralgia in USA (unspecified route) before March 2021 (Oxford Cannabinoid Technologies, March 2021)